Previous research has shown that vitamin D deficiency can increase the risk of multiple sclerosis (MS) — and a new study ...

Treatment with high-dose vitamin D reduced disease activity in people with clinically isolated syndrome in a Phase 3 trial.

Researchers from CHU Nîmes, Université Montpellier, and multiple MS centers in France have found that oral cholecalciferol in doses of 100,000 IU every two weeks significantly reduced disease activity ...

Tom Nolan reviews this week’s research There are so many studies published about vitamin D—about a dozen each day—it’s hard to keep up. One that stands out is a double-blind randomised controlled ...

A new study from researchers in France has found that taking high doses of vitamin D every two weeks may help reduce disease ...

A significant benefit was observed with Tysabri over Rebif in delaying SPMS disability progression when therapeutic lag was accounted for.

Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) ...

High-dose oral cholecalciferol (vitamin D3) supplementation significantly reduced disease activity in patients with clinically isolated syndrome (CIS) suggestive of multiple sclerosis (MS ...

Walk MS is two weeks away, and more than 1,500 people in the area are hard at work fundraising and building their teams.

Cycle Pharmaceuticals Limited (Cycle) is pleased to announce that Cycle Vita is now available with BAFIERTAM, expanding its patient support services in MS, following the acquisition of Banner Life ...